Compare BioNTech SE - ADR (BNTX) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Equinor ASA — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while Equinor ASA trades at $40.72 (market cap $97.58B). The key difference: Equinor ASA is far larger — about 4.2× BioNTech SE - ADR's market cap, and Equinor ASA pays a 3.81% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | EQNR | |
|---|---|---|
Market Cap | $23.31B | $97.58B |
Sector | Health | Energy |
52-Week High | $119.34 | $42.40 |
52-Week Low | $83.89 | $22.41 |
Enterprise Value | $6.60B | $106.28B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
EQNR trades at $40.99, up 5.32% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 40% year-over-year despite an earnings miss, driven by higher energy prices and production. Recent news highlights a 22.2% monthly rally and ongoing share buybacks. Valuation ratios appear attractive with a P/E of 11.09 and EV/EBITDA of 2.3, while profitability metrics like a 21.32% ROE indicate efficient capital use.
The outlook for EQNR is positive, with opportunities from strategic investments in subsea projects and sustained cash flow generation supporting dividends and buybacks. Risks include volatility in oil and gas prices, execution challenges in growth projects, and potential regulatory shifts impacting energy markets. Analyst sentiment is mixed but leans cautious, with 56.53% holding a neutral stance amid valuation concerns after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
